Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Brean Murray Ups Adolor to Strong Buy


Brean Murray upgraded Adolor (ADLR) to strong buy from accumulate, citing expectations for positive results from trials of the company's new treatment for obstructive bowel disease.

Analyst Jonathan Aschoff notes very clean Phase 2 trial results presented thus far in 522 patients who used the treatment. He thinks regulatory approval of the treatment would be material to the company's profitability, given factors such as the appeal of an oral medication for obstructive bowel disease. He says shares have drifted several dollars lower over the past two months, but he believes significant upside potential exists in them. He has $34 stock price target.


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus